Literature DB >> 33377547

Current treatments for atopic dermatitis in Japan.

Kyohei Miyano1,2, Yuichiro Tsunemi1.   

Abstract

The goal of a treatment regimen for atopic dermatitis is to reach and maintain a state where the patient exhibits mild symptoms or an absence of symptoms, and the patient should not experience disturbance during daily activities. The basis of a treatment regimen for atopic dermatitis is topical therapy, and currently there exist topical corticosteroids, tacrolimus and delgocitinib. Using these, proactive therapy is performed as maintenance therapy after remission induction therapy. However, in cases of moderate to severe atopic dermatitis, topical drugs alone cannot induce remission and systemic therapies such as cyclosporin, ultraviolet therapy, and dupilumab should be used in combination. In particular, dupilumab has many advantages such as high efficacy, relatively few adverse reactions, and ease of use in elderly patients with severe atopic dermatitis. In this review, we present a treatment algorithm for atopic dermatitis that emphasizes the importance of maintaining remission after induction of remission, and summarizes the characteristics of current medication therapy for atopic dermatitis in Japan.
© 2020 Japanese Dermatological Association.

Entities:  

Keywords:  atopic dermatitis; corticosteroid; delgocitinib; dupilumab; tacrolimus

Mesh:

Substances:

Year:  2020        PMID: 33377547     DOI: 10.1111/1346-8138.15730

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  2 in total

1.  Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic.

Authors:  Soichiro Kado; Koji Kamiya; Megumi Kishimoto; Takeo Maekawa; Aya Kuwahara; Junichi Sugai; Mayumi Komine; Mamitaro Ohtsuki
Journal:  J Dermatol       Date:  2021-09-21       Impact factor: 4.005

2.  Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate-to-severe atopic dermatitis: Two-year data from the ADDRESS-J disease registry.

Authors:  Norito Katoh; Hidehisa Saeki; Yoko Kataoka; Takafumi Etoh; Satoshi Teramukai; Hiroki Takagi; Hiroyuki Fujita; Marius Ardeleanu; Elena Rizova; Kazuhiko Arima
Journal:  J Dermatol       Date:  2022-06-17       Impact factor: 3.468

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.